[{"id":"0c094526-6b1e-4e8d-b65c-6feabab8a313","acronym":"ANGLeD","url":"https://clinicaltrials.gov/study/NCT03613181","created_at":"2021-01-18T17:45:29.869Z","updated_at":"2024-07-02T16:35:49.783Z","phase":"Phase 3","brief_title":"ANG1005 in Leptomeningeal Disease From Breast Cancer","source_id_and_acronym":"NCT03613181 - ANGLeD","lead_sponsor":"Angiochem Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Halaven (eribulin mesylate) • methotrexate IV • paclitaxel trevatide (ANG1005)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-24"},{"id":"0a4d813f-a8eb-4862-8420-722af4ec96d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01679743","created_at":"2021-01-18T07:16:36.856Z","updated_at":"2024-07-02T16:36:53.631Z","phase":"Phase 2","brief_title":"GRN1005 for Brain Metastases From Breast or Lung Cancer","source_id_and_acronym":"NCT01679743","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel trevatide (ANG1005)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/29/2012","start_date":" 08/29/2012","primary_txt":" Primary completion: 08/11/2014","primary_completion_date":" 08/11/2014","study_txt":" Completion: 08/11/2014","study_completion_date":" 08/11/2014","last_update_posted":"2019-11-15"},{"id":"ad5a3870-7a45-4108-85c7-54a7bc4d2a36","acronym":"GRABM-B","url":"https://clinicaltrials.gov/study/NCT01480583","created_at":"2021-01-18T06:10:55.332Z","updated_at":"2024-07-02T16:37:30.627Z","phase":"Phase 2","brief_title":"GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases","source_id_and_acronym":"NCT01480583 - GRABM-B","lead_sponsor":"Angiochem Inc","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel trevatide (ANG1005)"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2016-07-13"}]